{
    "topic": "opioid_crisis",
    "source": "Axios",
    "bias": 1,
    "url": "https://www.axios.com/drug-price-increases-2020-pfizer-gilead-475dbce9-d75a-4ff2-804c-a8289bb35f74.html",
    "title": "Drug price hikes are back for 2020",
    "date": "2020-01-02",
    "authors": "",
    "content": "Between the lines : Political pressure has forced some drugmakers to consider fewer price hikes on their medicines or to keep the increases in single-digit percentages .\nRaising prices does n't necessarily mean net drug spending ( after rebates and other discounts given to health insurers ) goes up \u2014 but it usually does , and many drug price increases are n't justifiable .\nThe price increases are salt in the wound following Congress ' failure to pass meaningful drug price legislation in 2019 , and are already being used to make the political case for action this year .\nBy the numbers : As of Friday , drug companies had increased the prices of 445 products by a median of 5 % , according to an analysis by 3 Axis Advisors . More hikes are expected throughout January .\nPfizer increased the prices of 58 drugs , the most of any company by far . Novartis , Allergan and GlaxoSmithKline each had counts in the twenties .\nWhat we 're seeing : Some of the biggest pharmaceutical companies are bumping up prices on popular brand-name drugs , according to pharmaceutical industry analyses from several investment firms and consulting firm 3 Axis Advisors .\nAbbVie : \u2b06\ufe0f 7.4 % on Humira , the world 's top-selling drug that is facing major competition and lower prices everywhere \u2014 except the U.S .\n\u2b06\ufe0f 7.4 % on Humira , the world 's top-selling drug that is facing major competition and lower prices everywhere \u2014 except the U.S. Biogen : \u2b06\ufe0f 6 % on Tecfidera , a multiple sclerosis drug that is facing a major patent lawsuit .\n\u2b06\ufe0f 6 % on Tecfidera , a multiple sclerosis drug that is facing a major patent lawsuit . Bristol-Myers Squibb : \u2b06\ufe0f 6 % on blood thinner Eliquis and \u2b06\ufe0f 1.5 % on Opdivo , an outpatient cancer drug that usually does n't have rebates .\n\u2b06\ufe0f 6 % on blood thinner Eliquis and \u2b06\ufe0f 1.5 % on Opdivo , an outpatient cancer drug that usually does n't have rebates . Celgene : \u2b06\ufe0f 6 % on cancer treatment Revlimid , which is now owned by Bristol-Myers Squibb .\n\u2b06\ufe0f 6 % on cancer treatment Revlimid , which is now owned by Bristol-Myers Squibb . Gilead : \u2b06\ufe0f 4.8 % on a host of medicines , including its main HIV drugs ( Truvada , Descovy and Biktarvy ) .\n\u2b06\ufe0f 4.8 % on a host of medicines , including its main HIV drugs ( Truvada , Descovy and Biktarvy ) . Merck : \u2b06\ufe0f 1.5 % on Keytruda , its blockbuster cancer infusion drug that competes with Opdivo and similarly does n't usually give back rebates .\n\u2b06\ufe0f 1.5 % on Keytruda , its blockbuster cancer infusion drug that competes with Opdivo and similarly does n't usually give back rebates . Novartis : \u2b06\ufe0f 7 % on Cosentyx , a major psoriasis treatment .\n\u2b06\ufe0f 7 % on Cosentyx , a major psoriasis treatment . Pfizer : \u2b06\ufe0f 5 % on breast cancer pill Ibrance and \u2b06\ufe0f 7.3 % on Prevnar , a vaccine that is the company 's best-selling drug .\n\u2b06\ufe0f 5 % on breast cancer pill Ibrance and \u2b06\ufe0f 7.3 % on Prevnar , a vaccine that is the company 's best-selling drug . Purdue Pharma : \u2b06\ufe0f 5 % on its OxyContin painkiller , all while the company sits in bankruptcy court and the Sackler owners dangle billions in public settlement funds .\nYes , but : List prices do n't reflect discounts and rebates , which reduce net prices . List prices do , however , affect people who have high deductibles or are uninsured .\nLooking ahead : Amgen , Eli Lilly and other companies have n't released any drug price increases yet , usually waiting until a few days or weeks after the start of the new year .\nThe bottom line : Congress these days is much better at doing nothing than passing legislation , and its inertia is only going to be made worse by the November election . Until something changes , expect increases to happen again .\nGo deeper : Drug makers still raising prices , but seeking fewer hikes",
    "content_original": "Between the lines: Political pressure has forced some drugmakers to consider fewer price hikes on their medicines or to keep the increases in single-digit percentages.\n\nRaising prices doesn't necessarily mean net drug spending (after rebates and other discounts given to health insurers) goes up \u2014 but it usually does, and many drug price increases aren't justifiable.\n\nThe price increases are salt in the wound following Congress' failure to pass meaningful drug price legislation in 2019, and are already being used to make the political case for action this year.\n\nBy the numbers: As of Friday, drug companies had increased the prices of 445 products by a median of 5%, according to an analysis by 3 Axis Advisors. More hikes are expected throughout January.\n\nPfizer increased the prices of 58 drugs, the most of any company by far. Novartis, Allergan and GlaxoSmithKline each had counts in the twenties.\n\nWhat we're seeing: Some of the biggest pharmaceutical companies are bumping up prices on popular brand-name drugs, according to pharmaceutical industry analyses from several investment firms and consulting firm 3 Axis Advisors.\n\nAbbVie: \u2b06\ufe0f 7.4% on Humira, the world's top-selling drug that is facing major competition and lower prices everywhere \u2014 except the U.S.\n\n\u2b06\ufe0f 7.4% on Humira, the world's top-selling drug that is facing major competition and lower prices everywhere \u2014 except the U.S. Biogen: \u2b06\ufe0f 6% on Tecfidera, a multiple sclerosis drug that is facing a major patent lawsuit.\n\n\u2b06\ufe0f 6% on Tecfidera, a multiple sclerosis drug that is facing a major patent lawsuit. Bristol-Myers Squibb: \u2b06\ufe0f 6% on blood thinner Eliquis and \u2b06\ufe0f 1.5% on Opdivo, an outpatient cancer drug that usually doesn't have rebates.\n\n\u2b06\ufe0f 6% on blood thinner Eliquis and \u2b06\ufe0f 1.5% on Opdivo, an outpatient cancer drug that usually doesn't have rebates. Celgene: \u2b06\ufe0f 6% on cancer treatment Revlimid, which is now owned by Bristol-Myers Squibb.\n\n\u2b06\ufe0f 6% on cancer treatment Revlimid, which is now owned by Bristol-Myers Squibb. Gilead: \u2b06\ufe0f 4.8% on a host of medicines, including its main HIV drugs (Truvada, Descovy and Biktarvy).\n\n\u2b06\ufe0f 4.8% on a host of medicines, including its main HIV drugs (Truvada, Descovy and Biktarvy). Merck: \u2b06\ufe0f 1.5% on Keytruda, its blockbuster cancer infusion drug that competes with Opdivo and similarly doesn't usually give back rebates.\n\n\u2b06\ufe0f 1.5% on Keytruda, its blockbuster cancer infusion drug that competes with Opdivo and similarly doesn't usually give back rebates. Novartis: \u2b06\ufe0f 7% on Cosentyx, a major psoriasis treatment.\n\n\u2b06\ufe0f 7% on Cosentyx, a major psoriasis treatment. Pfizer: \u2b06\ufe0f 5% on breast cancer pill Ibrance and \u2b06\ufe0f 7.3% on Prevnar, a vaccine that is the company's best-selling drug.\n\n\u2b06\ufe0f 5% on breast cancer pill Ibrance and \u2b06\ufe0f 7.3% on Prevnar, a vaccine that is the company's best-selling drug. Purdue Pharma: \u2b06\ufe0f 5% on its OxyContin painkiller, all while the company sits in bankruptcy court and the Sackler owners dangle billions in public settlement funds.\n\nYes, but: List prices don't reflect discounts and rebates, which reduce net prices. List prices do, however, affect people who have high deductibles or are uninsured.\n\nLooking ahead: Amgen, Eli Lilly and other companies haven't released any drug price increases yet, usually waiting until a few days or weeks after the start of the new year.\n\nThe bottom line: Congress these days is much better at doing nothing than passing legislation, and its inertia is only going to be made worse by the November election. Until something changes, expect increases to happen again.\n\nGo deeper: Drug makers still raising prices, but seeking fewer hikes",
    "source_url": "www.axios.com",
    "bias_text": "center",
    "ID": "ovS922HraDfSWH85"
}